Fostering Antibiotic Development through Impact Funding.

New antibiotics are critical to staying ahead of antimicrobial resistance, yet the return on investment in anti-infective development is a serious obstacle to commercial research. The REPAIR Impact Fund is designed to foster continued innovation until structural changes in the market provide sufficient incentives for investment.

The global preclinical antibacterial pipeline.

Antibacterial resistance is a great concern and requires global action. A critical question is whether enough new antibacterial drugs are being discovered and developed. A review of the clinical antibacterial drug pipeline was recently published, but comprehensive information about the global preclinical pipeline is unavailable.